Free Trial
ASX:OPT

Opthea (OPT) Stock Price, News & Analysis

Opthea logo

About Opthea Stock (ASX:OPT)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
504,572 shs
Average Volume
N/A
Market Capitalization
$790.69 million
P/E Ratio
N/A
Dividend Yield
0.24%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Receive OPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Opthea and its competitors with MarketBeat's FREE daily newsletter.

OPT Stock News Headlines

How Trade Wars Are Creating Fresh Opportunities for Investors
Tariffs and trade tensions are back in the headlines, and while many are focused on the risks, smart investors know there’s also opportunity. New supply chain shifts, pricing power adjustments, and sector revaluations are already underway—creating openings for those who act early. That’s why we’ve just released our latest research: 📈 “From Tariffs to Returns: How to Capitalize on Trade Disputes in Your Portfolio”
See More Headlines

OPT Stock Analysis - Frequently Asked Questions

Opthea Limited (ASX:OPT) issued its quarterly earnings results on Friday, August, 9th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.00. Opthea had a negative net margin of 182,616.58% and a positive trailing twelve-month return on equity of 543.34%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Opthea investors own include Skyworks Solutions (SWKS), Teladoc Health (TDOC), Vaxart (VXRT), Zion Oil & Gas (ZN), AST SpaceMobile (ASTS), Appian (APPN) and American Well (AMWL).

Company Calendar

Last Earnings
8/09/2019
Today
5/31/2025

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
Current Symbol
ASX:OPT
CIK
N/A
Fax
N/A
Employees
8
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$220.24 million
Net Margins
-182,616.58%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$199,005.00
Price / Cash Flow
10.29
Book Value
A($0.11) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
1,230,000,000
Free Float
N/A
Market Cap
$790.69 million
Optionable
Not Optionable
Beta
1.61
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (ASX:OPT) was last updated on 5/31/2025 by MarketBeat.com Staff
From Our Partners